BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD
10.76
+0.59 (5.80%)
Jun 24, 2022 4:00 PM EDT - Market closed
5.80%
Market Cap 2.00B
Revenue (ttm) 188.03M
Net Income (ttm) -193.97M
Shares Out 185.58M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,539,189
Open 10.25
Previous Close 10.17
Day's Range 10.19 - 10.91
52-Week Range 7.61 - 19.99
Beta 2.51
Analysts Buy
Price Target 17.80 (+65.4%)
Earnings Date Aug 4, 2022

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 in... [Read more...]

Industry Biotechnology
IPO Date Mar 3, 1994
CEO Jon Stonehouse
Employees 358
Stock Exchange NASDAQ
Ticker Symbol BCRX
Full Company Profile

Financial Performance

In 2021, BCRX's revenue was $157.17 million, an increase of 782.38% compared to the previous year's $17.81 million. Losses were -$184.06 million, 0.68% more than in 2020.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 17.8, which is an increase of 65.43% from the latest price.

Price Target
$17.8
(65.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunolo...

RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and ...

Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

RESEARCH TRIANGLE PARK, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma Gmb...

Why BioCryst Pharmaceuticals Topped the Market Today

The company receives some good news from a top regulator.

FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250

RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designati...

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention ...

RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) fo...

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference in New ...

7 Cheap Biotech Stocks to Buy Now

These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on Investo...

Why BioCryst Stock Lost Nearly 4% of Its Value Today

The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

—Q1 2022 ORLADEYO net revenue of $49.7 million—

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 23 n...

Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why BioCryst Stock Shot Nearly 5% Higher Today

The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.

7 Top-Rated Biotech Stocks to Buy for Q2

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

BioCryst to Report First Quarter 2022 Financial Results on May 5

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thurs...

After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?

Things aren't actually that bad.

Why BioCryst Pharmaceuticals Stock Sank Today

Another analyst gets notably less enthusiastic about the company's prospects.

Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week

Investors returned to the stock after last week's sell-off.

Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down

BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases

Why BioCryst Pharmaceuticals Stock Is Falling

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.  BofA Securities analyst Tazeen A...

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthcare...

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not...

Why BioCryst Pharmaceuticals Stock Is Crashing Today

The company is pausing patient enrollment in three clinical studies.